Introducing the Galleri multi-cancer early detection test

Galleri is a blood test that can detect 50+ cancer types and can be taken annually.1,2

Request your Galleri test

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Roger testimonial

Patient Story: Roger, Cancer Signal Detected with the Galleri test

Patient Story: Roger, Cancer Signal Detected with the Galleri test

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Who is eligible?

The Galleri test is available as an in-network, annual benefit for eligible members under an Autodesk UnitedHealthcare (UHC) medical plan. Eligible members are those who meet the eligibility criteria listed below.

Members

  • Enrolled in an Autodesk UnitedHealthcare (UHC) Medical Plan
  • 50 years and older
  • 40-49 with risk factors 
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 3 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic hepatitis B or C infection
    • Infection with certain strains of HPV (e.g., HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 40-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First-degree relative with cancer†
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2

*Excludes basal or squamous cell carcinoma of the skin.

†Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.

woman with brown hair wearing a tan sweater and gray pants smiling softly and sitting on a chair in her living room

Limited data exists regarding the performance of the Galleri test in individuals <50 years of age.2,3,4

Galleri for Autodesk

Eligibility

The Galleri test is available as an in-network, annual benefit for eligible members under all Autodesk UnitedHealthcare medical plans.

See eligibility information

Accessing the test

Please use your personal email address to create an account.

Frequently Asked Questions

Screen for more in 4 simple steps

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

It will take about 10 minutes to complete an online health questionnaire about your medical history. The Galleri test, by GRAIL, is available by prescription only. By requesting the test and completing the questionnaire, you’re requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine provider confirms your eligibility and prescribes the Galleri test, you will receive a notification via email and a collection kit in the mail. Visit Galleri.com/schedule to book your blood draw appointment at a GRAIL blood draw partner.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

Bring your test kit and Test Requisition Form (TRF) with you to the appointment. A trained technician will draw your blood sample and ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will contact you when your result is ready — about 2-3 weeks after your blood is received at the GRAIL lab.

What does the Galleri test result mean?


The Galleri test detected DNA fragments associated with cancer in your blood sample. About 1 out of every 100 test has a Cancer Signal Detected result.4

This result will also include a prediction of the issue type or organ associated with the cancer signal, called a Cancer Signal Origin (CSO). This provides direction to your doctor on the cancer’s origin and can help guide the next steps for diagnosis.2,5

In a clinical study, around 6 out of 10 people with a Cancer Signal Detected result were diagnosed with cancer after diagnostic testing.6*

*Based on the first ~25,000 participants with 1 year of follow-up. 

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cancer signal detected thumb
NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing. Such testing may include lab work or imagining ordered by your healthcare provider to confirm cancer.

The Galleri test did not detect DNA fragments associated with cancer in your blood sample. 

Nearly 99% of people who use the Galleri test will screen negative.4

This result does not completely rule out the possibility of cancer. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, making them unlikely to be detected through a blood test (e.g., brain, skin, and early-stage breast and prostate cancers).7 False positive and false negative results do occur. This result does not predict whether you will develop cancer in the future. 

Cancer signal not detected thumb
NEXT STEPS

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur, as this could lead to delayed diagnosis.

Cancer can be unpredictable. The Galleri test can be taken as a simple blood test. Adding the Galleri test to an annual routine can improve your chance of finding cancer early.8

Cancer screening with Galleri can make a difference

Galleri looks for many deadly cancers before symptoms appear from a single blood draw and identifies a unique “fingerprint” of 50+ cancers, including many without a recommended screening available today.
  • Jackie

    Patient testimonial: Jackie

    Cancer Signal Detected
    Read Jackie's full story

  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary

    Cancer Signal Detected

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected
    Read Jennifer's full story

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected
    Read Rich & Staci's full story

  • Oncologist perspective

    Oncologist Perspectives

1 / 12

Frequently Asked Questions for Autodesk

Additional Frequently Asked Questions about the Galleri test

The Galleri test is available as an annual, in-network, benefit for eligible members under an Autodesk UnitedHealthcare medical plan (Choice Plus PPO, Choice Plus High Deductible, or Choice EPO). Eligible members are those who are age 50 and older, or age 40-49 with specific risk factors. 

To access the Galleri test as a covered benefit, you must request the test through this webpage.

When requesting through this website, an independent healthcare provider from Recuro Health will review your request and order the test if appropriate. The test is prescription only.

Please have your UnitedHealthcare medical ID card ready.

  • Enter your Name, Group Number, and Member ID Number exactly as they appear on your UnitedHealthcare medical ID card (example card).
  • If your Group ID does not appear in the drop-down menu, you are not eligible for the Galleri benefit through Autodesk. Call 833-694-2553 if you have questions or wish to order the test and make alternate payment arrangements.

For eligible members of an Autodesk UnitedHealthcare medical plan, the cost of the Galleri test and laboratory fees are covered at no cost.

An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you at Galleri.com/schedule.

Please note, the blood draw associated with the Galleri test must occur on a date you are covered under this employee benefit. Members are responsible for the full cost of the test when it is obtained via any other means, such as through a personal physician, or when the blood draw date of service ovvurs when benefit coverage is not in effect.

If you are not eligible for the benefit under Autodesk program, you may be able to use pre-tax dollars in your flexible spending account (FSA) or health savings account (HSA) to pay for the Galleri test on galleri.com. Check with your FSA or HSA administrator to determine eligibility.

Under the Autodesk benefit program, employees and dependents eligible for the Galleri test can request the Galleri test once every 12 months.

To access the Galleri test as a covered benefit, you must request the test through this web page. An independent physician from Recuro Health will review your request and order the test, if appropriate.

If you are not an eligible member, your primary care physician may order the test on your behalf, but you will be responsible for the full cost of the test. Call 833-694-2553 if you wish to order the Galleri test through your primary care physician and make arrangements for direct payment.

For eligible members of an Autodesk UnitedHealthcare medical plan, the cost of the Galleri test and laboratory fees are covered at no cost. An at-home or in-lab blood draw is included in the price of the test if it is scheduled with one of our partner labs. Find a time and location convenient for you at Galleri.com/schedule. 

The blood draw associated with Galleri must occur on a date you are covered under this benefit. Members are responsible for the full cost of the test when obtained via any other means such, as through a personal physician, or when the blood draw date of service occurs when benefit coverage is not in effect.

This benefit does not cover any follow-up consultations, diagnostic procedures (e.g., imaging, biopsies, other laboratory tests), and/or treatment plans that your healthcare provider may recommend for you in the event of a Galleri “Cancer Signal Detected” test result. Such services may be covered by your medical plan, in accordance with the Summary Plan Description. Please contact Member Services via the phone number listed on the back of your medical insurance card to determine plan coverage and the costs you may incur related to your healthcare provider’s recommendations.

After taking the Galleri test, you may receive an explanation of benefits (EOB) from UnitedHealthcare. The EOB details the amount you are expected to pay, which should be $0. If your EOB indicates you have a payment responsibility, please call the GRAIL Billing Support Team at 833-694-2553 and select option two (Billing). Our team will discuss how we can assist.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  3. Matrana M, Shukla V, Kingsbury D, et al. Real‑world data and clinical experience from over 100,000 multi‑cancer early detection tests [poster]. American Association for Cancer Research (AACR) Annual Meeting; 2025 Apr 25-30; Chicago. https://assets.grail.com/wp-content/uploads/2025/04/7202.Matrana.AACR-2025-RWE-100K_Poster_Final.pdf
  4. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2
  5. GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
  6. Nabavizadeh N, et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER2 study [proffered presentation]. European Society for Medical Oncology (ESMO) Annual meeting: 2025 Oct 17-21; Berlin.
  7. Bredno J, Venn O, Chen X, et al. Circulating tumor DNA allele fraction: a candidate biological signal for multi-cancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022; 192(10):1368-78. doi:10.1016/j.ajpath.2022.07.007
  8. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.